FDA Accepts Supplement for PARLODEL by Esjay Pharma
The FDA has accepted a supplemental application for PARLODEL (bromocriptine mesylate) from Esjay Pharma.
Asset / Drug
Drug and asset intelligence for PARLODEL with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Dopamine Agonist
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.